SCHOOL OF MEDICINE

Department of Medicine

IU Liver Research

Primary Sclerosing Cholangitis

 

Primary Sclerosing Cholangitis team

Primary Sclerosing Cholangitis damages and blocks bile ducts inside and outside the liver. While the cause is not known, genes, immune system problems, bacteria and viruses may play roles in the development of the disease.


Current studies:

Intercept 207 OSC Study
Enrolling: Yes
Duration: 6 months with optional 2-year LTSE
Primary Outcomes measured: Evaluate the effects of OCA on ALP in subjects; evaluate the effects of OCA on safety in subjects with PSC
Drug(s): obeticholic acid and placebo

Contact information:
Rachel Lee
317-278-6266
Lee352@iu.edu


NGM 15-106 PSC Study
Enrolling: No
Duration: 22 weeks total, 12 week treatment period
Primary Outcomes measured: The mean and percent change in ALP from Baseline to Week 12
Drug(s): NGM282 or Placebo, 1:1:1 Ratio. Daily subcutaneous injection

Contact information:
Rachel Lee
317-278-6266
Lee352@iu.edu


PROGRESS
Enrolling: Yes
Duration
: 1 visit

Contact information:
Megan Comerford
317-278-9226
mcomerfo@iu.edu